Changeflow GovPing Pharma & Drug Safety Heterocyclic Compound Orexin 2 Receptor Agonist...
Routine Notice Added Final

Heterocyclic Compound Orexin 2 Receptor Agonist Narcolepsy Treatment

Favicon for changeflow.com ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260092033A1 for a heterocyclic compound as an orexin 2 receptor agonist for treating narcolepsy. Inventors include researchers from a Japanese pharmaceutical company. The application claims priority to Application No. 19287436 filed July 31, 2025. This is a standard pharmaceutical patent filing that does not impose regulatory obligations on third parties.

What changed

The USPTO published patent application US20260092033A1 on April 2, 2026, covering heterocyclic compounds having orexin type 2 receptor agonist activity for the prophylaxis or treatment of narcolepsy. The application includes detailed chemical structure claims (Formula I) and lists 14 named inventors. CPC classifications include C07D 207/14, C07D 403/06, C07D 407/08, and C07D 417/06.

Patent applications do not create compliance obligations or deadlines for third parties. Compliance teams should note this filing for competitive intelligence and freedom-to-operate analysis in the narcolepsy treatment space. No action is required regarding this publication.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

HETEROCYCLIC COMPOUND AND USE THEREOF

Application US20260092033A1 Kind: A1 Apr 02, 2026

Inventors

Yasushi HATTORI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO

Abstract

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

CPC Classifications

C07D 207/14 C07D 403/06 C07D 407/08 C07D 417/06

Filing Date

2025-07-31

Application No.

19287436

View original document →

Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260092033A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent Filing Pharmaceutical Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Intellectual Property
Topics
Intellectual Property Healthcare

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.